HWM
NBIX icon

HighMark Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

HighMark Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-57
Closed -$8K – 634
2025
Q3 		$8K Hold
57
– – ﹤0.01% 334
2025
Q2 		$7.16K Buy
57
+18
+46% +$2.06K ﹤0.01% 352
2025
Q1 		$4.31K Hold
39
– – ﹤0.01% 384
2024
Q4 		$5.32K Buy
39
+14
+56% +$1.73K ﹤0.01% 374
2024
Q3 		$2.88K Sell
25
-15
-38% -$2.06K ﹤0.01% 453
2024
Q2 		$5.51K Sell
40
-20
-33% -$2.74K ﹤0.01% 375
2024
Q1 		$8.28K Buy
60
+3
+5% +$410 0.01% 312
2023
Q4 		$7.51K Hold
57
– – 0.01% 309
2023
Q3 		$6.41K Hold
57
– – 0.01% 319
2023
Q2 		$5.38K Buy
57
+2
+4% +$195 ﹤0.01% 340
2023
Q1 		$5.57K Hold
55
– – ﹤0.01% 377
2022
Q4 		$6.57K Sell
55
-6
-10% -$703 0.01% 307
2022
Q3 		$6K Hold
61
– – 0.01% 310
2022
Q2 		$6K Sell
61
-4
-6% -$369 ﹤0.01% 323
2022
Q1 		$6K Hold
65
– – ﹤0.01% 342
2021
Q4 		$6K Hold
65
– – ﹤0.01% 345
2021
Q3 		$6K Sell
65
-3
-4% -$283 ﹤0.01% 327
2021
Q2 		$7K Sell
68
-12
-15% -$1.15K 0.01% 313
2021
Q1 		$8K Buy
80
+51
+176% +$5.35K 0.01% 275
2020
Q4 		$3K Buy
+29
New +$2.8K ﹤0.01% 386

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

HighMark Wealth Management's NBIX Position: Q4 2025 in Review

HighMark Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 57 shares — an estimated $8K sold.

HighMark Wealth Management first reported a position in NBIX in Q4 2020 and held it in 20 quarters. The position peaked at $8.28K in Q1 2024. 732 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • HighMark Wealth Management reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • HighMark Wealth Management sold 57 Neurocrine Biosciences shares in Q4 2025, an estimated $8K.
  • HighMark Wealth Management first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 20 quarters.
  • HighMark Wealth Management's Neurocrine Biosciences position peaked at $8.28K in Q1 2024.
  • 732 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on HighMark Wealth Management's 13F filing for Q4 2025, filed 5 Feb 2026.